Drug-eluting stents should not be the favoured option for treating saphenous vein graft lesions according conclusions from a registry analysis presented to the American Heart Association conference by
Drug-eluting stents should not be the favoured option for treating saphenous vein graft lesions according conclusions from a registry analysis presented to the American Heart Association conference byJeff Trostfrom Johns Hopkins in Baltimore.
Related Episodes
TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?
Gregg Stone REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GREGG STONE, Columbia University, New York New light has been thrown on the u
Long Term Outcomes of Drug Eluting and Bare Metal Stents in Patients Undergoing PCI
Laura Mauri Raymond Gibbons REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida LAURA MAURI, Brigham and Woman’s Hospit
Patients with High Restenosis Risk Benefit More from Drug Eluting Stents
Raul Moreno REFERENCE: Abstract 3103, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria RAUL MORENO, University Hospital La Paz, Madrid Results from a large meta analysis s